Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
27/12/2022
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
20/12/2022
Nykode Therapeutics announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
19/12/2022
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership
06/12/2022
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer
23/11/2022
Nykode Therapeutics reports 3Q 2022 Financial Results
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
